Health Advisory: Shortage of Purified Protein Derivative (PPD) Solution for Tuberculin Skin Testing

Nancy Leveille and Lisa Volk in Clinical & Quality

On June 6, 2019 the Centers for Disease Control and Prevention issued a Health Advisory (CDC-HAN-00420) providing notification of an anticipated three to ten-month shortage of Aplisol ®, a product of Par Pharmaceuticals. At this time, there is availability of the other FDA-approved solution, Tubersol ®, a product of Sanofi Pasteur. Please distribute to the Chief Medical Officer, Infection Control Department, Infectious Disease Department, Director of Nursing, AND Primary Care Clinics. See attached for full advisory.


Nancy Leveille, RN, MS
Executive Director
518-462-4800 x20

Lisa Volk, RN, B.P.S., LNHA
Director, Clinical & Quality Services
462-4800 x15